Naturex’s first-half 2013 revenue rose 12.6%, or 13.4% at constant exchange rates, from a year-ago, particularly due to the company's strategy to optimize the group's marketing and sales approach.
Changes in the group structure contributed an additional gain of 2.4%, mainly from the business of DBS acquired in 2012 whose cranberry-extract based product, Pacran, had strong performances for the period within the Natlife range.
For the first half, the company’s restated revenue rose to €165.8 million from restated first-half revenue of €147.2 million a year earlier.
Net income attributable to the group rose 4.2% to €10.1 million for the first half from restated net income of €9.7 million a year ago.
However, the company said growth is expected to be less robust in the second half due to the high comparison base with the same period in 2012. Furthermore, group restructuring measures will continue to marginally impact current operating income.
